A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients with Heavily Pretreated Relapsed Lymphoma
Treatment outcomes have improved in lymphoid malignancies but relapse remains inevitable in most patients. Everolimus (RAD) and lenalidomide (LEN) have shown clinical activity as single agents in patients with relapsed and refractory (R/R) Hodgkin and non-Hodgkin lymphomas. This Phase I/II trial for patients with R/R lymphoid malignancy opened at Mayo Clinic between January 2011 and May 2013 utilized a standard cohort of 3+3 design to determine the Maximum Tolerated Dose(MTD) of the combination.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Leslie Padrnos, Brenda Ernst, Amylou C. Dueck, Heidi E. Kosiorek, Brenda F. Ginos, Angela Toro, Patrick B. Johnston, Thomas M. Habermann, Jose F. Leis, Joseph R. Mikhael, Grzegorz S. Nowakowski, Joseph Colgan, Luis Porrata, Stephen M. Ansell, Thomas E. Wi Tags: Original Study Source Type: research